86 related articles for article (PubMed ID: 3965633)
21. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic factors in low-grade lymphoma].
Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A
Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223
[TBL] [Abstract][Full Text] [Related]
23. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.
Jones SE; Miller TP; Connors JM
J Clin Oncol; 1989 Sep; 7(9):1186-91. PubMed ID: 2671279
[TBL] [Abstract][Full Text] [Related]
25. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
26. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
27. Diffuse large-cell lymphoma of the testis.
Tondini C; Ferreri AJ; Siracusano L; Valagussa P; Giardini R; Rampinelli I; Bonadonna G
J Clin Oncol; 1999 Sep; 17(9):2854-8. PubMed ID: 10561362
[TBL] [Abstract][Full Text] [Related]
28. A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma.
Lee R; Cabanillas F; Bodey GP; Freireich EJ
J Clin Oncol; 1986 Oct; 4(10):1455-61. PubMed ID: 2428947
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma.
Hong J; Yoon HH; Ahn HK; Sym SJ; Park J; Park PW; Ahn JY; Park S; Cho EK; Shin DB; Lee JH
Acta Haematol; 2013; 130(4):305-11. PubMed ID: 24008775
[TBL] [Abstract][Full Text] [Related]
30. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases.
Straus DJ; Huang J; Testa MA; Levine AM; Kaplan LD
J Clin Oncol; 1998 Nov; 16(11):3601-6. PubMed ID: 9817281
[TBL] [Abstract][Full Text] [Related]
32. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
33. Primary small-intestinal lymphomas in Taiwan: immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease.
Shih LY; Liaw SJ; Dunn P; Kuo TT
J Clin Oncol; 1994 Jul; 12(7):1375-82. PubMed ID: 8021727
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in primary gastric lymphoma.
Medina-Franco H; Germes SS; Maldonado CL
Ann Surg Oncol; 2007 Aug; 14(8):2239-45. PubMed ID: 17546474
[TBL] [Abstract][Full Text] [Related]
35. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.
Dana BW; Dahlberg S; Miller TP; Hartsock RJ; Balcerzak S; Coltman CA; Carden JO; Hartley K; Fisher RI
J Clin Oncol; 1990 Jul; 8(7):1155-62. PubMed ID: 1694233
[TBL] [Abstract][Full Text] [Related]
36. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
37. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
38. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
Seker M; Bilici A; Ustaalioglu BO; Yilmaz B; Ozturk B; Ünal A; Dane F; Ozdemir NY; Elkiran ET; Kalender ME; Gumus M; Benekli M
Arch Gynecol Obstet; 2011 Aug; 284(2):405-9. PubMed ID: 20872226
[TBL] [Abstract][Full Text] [Related]
40. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]